Adams A, Scheckel B, Habsaoui A, Haque M, Kuhr K, Monsef I
Cochrane Database Syst Rev. 2022; 6:CD012633.
PMID: 35724934
PMC: 9208863.
DOI: 10.1002/14651858.CD012633.pub2.
Bohlius J, Tonia T, Nuesch E, Juni P, Fey M, Egger M
Br J Cancer. 2014; 111(1):33-45.
PMID: 24743705
PMC: 4090721.
DOI: 10.1038/bjc.2014.171.
Gao S, Ma J, Lu C
Tumour Biol. 2013; 35(1):603-13.
PMID: 23959477
DOI: 10.1007/s13277-013-1084-5.
Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O
Cochrane Database Syst Rev. 2012; 12:CD003407.
PMID: 23235597
PMC: 8145276.
DOI: 10.1002/14651858.CD003407.pub5.
Pronzato P, Cortesi E, van der Rijt C, Bols A, Moreno-Nogueira J, de Oliveira C
Oncologist. 2010; 15(9):935-43.
PMID: 20798194
PMC: 3228044.
DOI: 10.1634/theoncologist.2009-0279.
Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes.
Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S, Bowers P
Br J Cancer. 2010; 102(2):301-15.
PMID: 20051958
PMC: 2816662.
DOI: 10.1038/sj.bjc.6605498.
Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients.
Candel V, Carrato Mena A, Diaz-Rubio Garcia E, Gascon Vilaplana P, Baron M, Martin Jimenez M
Clin Transl Oncol. 2009; 11(11):727-36.
PMID: 19917536
DOI: 10.1007/s12094-009-0435-6.
Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.
Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J
Cochrane Database Syst Rev. 2009; (3):CD007303.
PMID: 19588423
PMC: 7208183.
DOI: 10.1002/14651858.CD007303.pub2.
Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis.
Tonelli M, Hemmelgarn B, Reiman T, Manns B, Reaume M, Lloyd A
CMAJ. 2009; 180(11):E62-71.
PMID: 19407261
PMC: 2683210.
DOI: 10.1503/cmaj.090470.
Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies.
Henry D
Drugs. 2007; 67(2):175-94.
PMID: 17284083
DOI: 10.2165/00003495-200767020-00002.
Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease).
Phernambucq E, Biesma B, Smit E, Paul M, vd Tol A, Schramel F
Br J Cancer. 2006; 95(4):470-4.
PMID: 16909132
PMC: 2360660.
DOI: 10.1038/sj.bjc.6603289.
Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer.
Fagnoni P, Limat S, Chaigneau L, Guardiola E, Briaud S, Schmitt B
Support Care Cancer. 2006; 14(10):1030-7.
PMID: 16802128
DOI: 10.1007/s00520-006-0062-5.
Clinical and economic impact of epoetins in cancer care.
Marchetti M, Barosi G
Pharmacoeconomics. 2004; 22(16):1029-45.
PMID: 15524492
DOI: 10.2165/00019053-200422160-00001.
Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline.
Vansteenkiste J, Tomita D, Rossi G, Pirker R
Support Care Cancer. 2004; 12(4):253-62.
PMID: 14740283
DOI: 10.1007/s00520-003-0583-0.
Erythropoietin, uncertainty principle and cancer related anaemia.
Clark O, Adams J, Bennett C, Djulbegovic B
BMC Cancer. 2002; 2:23.
PMID: 12270068
PMC: 130027.
DOI: 10.1186/1471-2407-2-23.
The level of haemoglobin in anaemic cancer patients correlates positively with quality of life.
Lind M, Vernon C, Cruickshank D, Wilkinson P, Littlewood T, Stuart N
Br J Cancer. 2002; 86(8):1243-9.
PMID: 11953880
PMC: 2375336.
DOI: 10.1038/sj.bjc.6600247.
Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy.
Demetri G
Br J Cancer. 2001; 84 Suppl 1:31-7.
PMID: 11308272
PMC: 2363900.
DOI: 10.1054/bjoc.2001.1750.
Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia.
Cremieux P, Finkelstein S, Berndt E, Crawford J, Slavin M
Pharmacoeconomics. 2000; 16(5 Pt 1):459-72.
PMID: 10662393
DOI: 10.2165/00019053-199916050-00004.
Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer.
Thatcher N, De Campos E, Bell D, Steward W, Varghese G, Morant R
Br J Cancer. 1999; 80(3-4):396-402.
PMID: 10408844
PMC: 2362337.
DOI: 10.1038/sj.bjc.6690369.
A risk-benefit assessment of epoetin in the management of anaemia associated with cancer.
Beguin Y
Drug Saf. 1998; 19(4):269-82.
PMID: 9804442
DOI: 10.2165/00002018-199819040-00003.
